CP-31398

p53 activator



BML-GR360-0010	10 mg	93.00 USD

BML-GR360-0050	50 mg	371.00 USD

CP-31398 restores mutant p53 tumor suppressor function in vitro without affecting p53 homologs p63 and p73, and in vivo inhibiting UVB-induced skin carcinogenesis in mice. Stabilization of p53 inhibits ubiquitination without altering phosphorylation at Ser¹² or Ser²⁰ or MDM2 binding. Administration of this or similar compounds has the potential to enhance cytotoxic chemotherapy.

Product Specification

Alternative Name:	N’-[2-[2-(4-Methoxyphenyl)ethenyl]-4-quinazolinyl]-N,N-dimethyl-1,3-propanediamine dihydrochloride

Formula:	C₂₂H₂₆N₄O·2HCl

MW:	435.4

Purity:	≥98% (TLC)

Appearance:	Yellow solid.

CAS:	259199-65-0

Solubility:	Soluble in water (25mg/ml) or DMSO (5mg/ml).

Long Term Storage:	-20°C

Use/Stability:	Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C.

Background / Technical Information:	Please click here for the comprehensive product datasheet.

Please mouse over

Product Literature References

The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells: C. Huang, et al.; Cancer Biol. Ther. 8, 2186 (2009), Abstract;

CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice: X. Tang, et al.; J. Clin. Invest. 117, 3753 (2007), Abstract;

CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73: M.J. Demma, et al.; J. Biol. Chem. 279, 45887 (2004), Abstract;

Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding: W. Wang, et al.; Mol. Cell Biol. 23, 2171 (2003), Abstract;

Characterization of the p53-rescue drug CP-31398 in vitro and in living cells: T.M. Rippin, et al.; Oncogene 21, 2119 (2002), Abstract;